US 11,739,298 B2
Genetically modified stem cells
Gerald F. Swiss, Rancho Santa Fe, CA (US); and David Kiewlich, Alameda, CA (US)
Assigned to SDF BioPharma Inc., Rancho Santa Fe, CA (US)
Filed by SDF BioPharma Inc., Rancho Santa Fe, CA (US)
Filed on Nov. 9, 2021, as Appl. No. 17/522,538.
Application 17/522,538 is a continuation of application No. 17/222,833, filed on Apr. 5, 2021, granted, now 11,186,827.
Application 17/222,833 is a continuation of application No. 16/826,104, filed on Mar. 20, 2020, granted, now 10,982,190, issued on Apr. 20, 2021.
Application 16/826,104 is a continuation of application No. 16/370,606, filed on Mar. 29, 2019, granted, now 10,696,950, issued on Jun. 30, 2020.
Application 16/370,606 is a continuation of application No. 16/146,980, filed on Sep. 28, 2018, abandoned.
Claims priority of provisional application 62/734,910, filed on Sep. 21, 2018.
Claims priority of provisional application 62/719,975, filed on Aug. 20, 2018.
Claims priority of provisional application 62/717,587, filed on Aug. 10, 2018.
Claims priority of provisional application 62/696,603, filed on Jul. 11, 2018.
Claims priority of provisional application 62/694,634, filed on Jul. 6, 2018.
Claims priority of provisional application 62/662,651, filed on Apr. 25, 2018.
Claims priority of provisional application 62/637,913, filed on Mar. 2, 2018.
Claims priority of provisional application 62/568,117, filed on Oct. 4, 2017.
Claims priority of provisional application 62/567,604, filed on Oct. 3, 2017.
Prior Publication US 2022/0145262 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 1/15 (2006.01); C12N 5/071 (2010.01); A61P 3/10 (2006.01); A61K 35/17 (2015.01); C12N 5/0783 (2010.01); C12N 5/0781 (2010.01); A61K 35/39 (2015.01); C07K 14/52 (2006.01)
CPC C12N 5/0676 (2013.01) [A61K 35/17 (2013.01); A61K 35/39 (2013.01); A61P 3/10 (2018.01); C07K 14/522 (2013.01); C12N 5/0635 (2013.01); C12N 5/0638 (2013.01); C12N 5/0646 (2013.01); C12N 5/0686 (2013.01); C12N 2501/998 (2013.01); C12N 2502/11 (2013.01); C12N 2502/99 (2013.01); C12N 2510/00 (2013.01)] 10 Claims
 
1. A population of isolated genetically engineered human beta cells comprising a nucleic acid encoding for exogenous or heterologous expression of a human CXCL12 protein isoform such that said population of said cells is characterized as encoding for the expression of a fugetactic amount of said CXCL12 protein isoform making said cell population resistant to cell death when in the presence of human immune cells in vitro as compared to a population of unengineered human beta cells,
wherein said population of genetically engineered human beta cells and said population of genetically unengineered human beta cells are obtained from a human stem cell that has been differentiated ex vivo into human beta cells,
wherein the nucleic acid is operably linked to an exogenous promoter,
wherein the nucleic acid encodes a human CXCL12 protein isoform that has an amino acid sequence identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6,
wherein the population of genetically engineered human beta cells produces insulin, and
wherein said population of genetically engineered human beta cells and said population of genetically unengineered human beta cells is either autologous or allogeneic.